Warning: session_start() expects parameter 1 to be array, string given in /home/k11lqezc/test.toscanalifesciences.org/wp-includes/class-wp-hook.php on line 286 Kedrion Biopharma - Toscana Life SciencesKedrion Biopharma - Toscana Life Sciences
Kedrion Biopharma is an Italian biopharmaceutical company that collects and fractionates blood plasma to produce and distribute plasma-derived therapies for use in treating patients suffering from hemophilia, immune deficiencies and other serious illnesses.
Kedrion puts people at its heart, placing a high value on the welfare of those who benefit from its products, as well as on the people and the communities it serves.
Kedrion acts as a bridge between donors and the people who need treatments, and works on a global scale to expand the patients’ access to available treatments. Headquartered in Italy, Kedrion Biopharma has a market presence in approximately 100 countries. In the field of plasma derivatives, it is the world’s 5th most important player and Italy’s 1st. The company employs more than 2300 people, over 1100 of whom are in Italy (850 in Tuscany): over 50% of staff are under the age of 40 and women account for 40% of the workforce.
Kedrion has six production plants: four in Italy - Bolognana (Lucca), Castelvecchio Pascoli (not operative yet, but in advanced phase of realization, and also in the Province of Lucca), Siena (dedicated to research and development of orphan drugs for the treatment of rare diseases) and Sant’Antimo (Naples) - one in Gödöllő, (Budapest, Hungary) and one in Melville (New York, USA).
As part of the PODs (Plasma Orphan Drugs) project funded by the Tuscany Region with POR CReO FESR 2007-2013, in collaboration with the Italian National Research Center in Pisa, in 2011 Kedrion developed an innovative pilot plant inside the TLS incubator, where a GMP facility was already present.
The IKOD site (Kedrion Orphan Drugs Facility) is dedicated to the production of pharmacologically active substances for the treatment of rare diseases such as:
Plasminogen developed for the treatment of ligneous conjunctivitis, for which the site has had Pharmaceutical Laboratory certification since October 2015 (aM-146/2015);
Factor V developed for the treatment of patients suffering from its deficiency in the coagulation cascade;
IKOD is also involved in the development and industrialization of pre-industrial scale processes as part of relevant business projects.